Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Evommune, Inc. (EVMN)

Evommune in-licenses EVO570 from Hinova and sells $30 million in private placement

Neutral Impact 4 of 5 m&a Written later

Evommune entered an exclusive license for Hinova Pharmaceuticals' VAV1 degraders, including EVO570, for all indications outside Greater China, paying a $20.0 million upfront cash payment plus warrants valued at $10.0 million. The company also agreed to sell 4,966,889 shares at $6.04 per share in a private placement expected to bring in gross proceeds of about $30 million, and estimates that cash plus these proceeds will fund operations into the second half of 2029.

Key points

  • License: $20.0 million upfront cash and pre-funded warrants for up to 1,262,413 shares, plus up to $150.0 million in development and regulatory milestones and up to $920.0 million in commercial milestones
  • Private placement: 4,966,889 shares at $6.04 per share, expected gross proceeds of about $30 million, expected to close on or about November 6, 2026
  • Company estimates pro forma cash of approximately $292.3 million, sufficient into the second half of 2029
  • Investors must file a Form S-3 resale registration within 60 days of closing

The filing

CompanyEvommune, Inc. (EVMN)
Form8-K, current report
Filed with the SECNov 4, 2026, 5:10 PM ET
Accession number0001193125-26-447608

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.